Companies

Isotechnika, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of immunosuppressive therapeutics for the treatment of autoimmune diseases and for use in the prevention of organ rejection in transplantation. Its lead compound includes ISA247, a calcineurin inhibitor, which is in European/Canadian Phase 3 clinical trial for the treatment of psoriasis; Phase 2b trial for the prevention of kidney rejection and transplantation; and Phase 2/Phase 3 trials for the treatment of uveitis.

Incyte Corporation operates as a drug discovery and development company, which focuses on developing proprietary small molecule drugs to treat human immunodeficiency virus (HIV), diabetes, oncology, and inflammation diseases.

Wilex AG, a biopharmaceutical company, focuses on the development of cancer therapies based on antibodies and small molecules. Its compounds under clinical development include WX-G250 (RENCAREX), WX-671, WX-UK1, CA9-SCAN, and WX-77x. The company’s WX-G250 (RENCAREX) is in Phase III registration ARISER trial as an antibody for the therapy of non-metastatic clear cell renal cell carcinoma; and WX-671 is a Phase II clinical trial candidate for the treatment of pancreatic cancer.

Oxygen Biotherapeutics, Inc. develops biotechnology products. It focuses on developing Oxycyte, a product alternative to transfused blood for use in surgical and similar medical situations. Oxycyte blood substitute product is a perfluorocarbon emulsified with water and a surfactant, which is provided to the patient intravenously. The properties of perfluorocarbon enable the product to gather oxygen from the lungs and transport the oxygen through the body releasing it along the way.

Onyx Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oral anticancer therapies designed to prevent cancer cell proliferation and angiogenesis by inhibiting proteins that signal or support tumor growth in the United States and internationally. The company’s product includes Nexavar, an orally active agent to operate through dual mechanisms of action by inhibiting angiogenesis and the proliferation of cancer cells.

Nabi Biopharmaceuticals, a biopharmaceutical company, develops products that address unmet medical needs in the areas of nicotine addiction and infectious disease. Its lead products in development include NicVAX, a nicotine conjugate and investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse; and StaphVAX, a Staphylococcus aureus and pentavalent vaccine, which is designed to prevent S.aureus infections, including those infections caused by antibiotic-resistant strains of S.aureus.

Lev Pharmaceuticals, Inc., a development stage biopharmaceutical company, develops and commercializes therapeutic products for the treatment of inflammatory diseases. It develops Cinryze (C1 inhibitor), which is a replacement therapy for the acute and prophylactic treatment of hereditary angioedema, also known as C1 inhibitor deficiency characterized by episodes of edema in the extremities, face, abdomen, and airway passages. The company’s products also include C1-INH intended for the treatment of other diseases and disorders, such as acute myocardial infarction or heart attack.

La Jolla Pharmaceutical Company, a biopharmaceutical company, develops pharmaceutical products to treat patients with lupus. The company's lead product in development is Riquent, which is in Phase 3 ASPEN clinical trials to treat patients with lupus. The Lupus is an antibody-mediated disease caused by abnormal B cell production of antibodies that attack healthy tissues. It also discovers and develops orally-active small molecules for the treatment of autoimmune diseases, and acute and chronic inflammatory disorders. The company was founded in 1989 and is based in San Diego, California.

CardioVascular BioTherapeutics, Inc., a development stage biopharmaceutical company, focuses on developing and marketing protein drug candidates used in the treatment of cardiovascular disease. The company uses an active pharmaceutical ingredient, the 141 acidic human form of fibroblast growth factor-1, in its drug candidates, which facilitates the growth of new blood vessels in the heart tissues and organs with an impaired vascular system.

Bioheart, Inc., a biotechnology company, focuses on discovering, developing, and commercializing autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate is MyoCell, a clinical therapy designed to populate regions of scar tissue in a patient’s heart with autologous muscle cells, or cells from the patient’s body for improving cardiac function in chronic heart failure patients.